Unlock the full potential of your AAV program with Xcite®: a proven path from gene to GMP by being faster, smarter, and more scalable
In the race to bring gene therapies to patients, everyday counts. But for many developers, the journey from discovery to GMP manufacturing is slowed by inconsistent yields, complex tech transfers, and scalability challenges that threaten timelines and budgets.
That's where Lonza's Xcite® AAV transient transfection platform comes in.
This white paper outlines how Xcite® is redefining what's possible in AAV manufacturing by offering a streamlined, serotype-agnostic solution that delivers high yields, robust quality, and seamless scalability. Whether you're in early development or preparing for commercial production, Xcite® gives you the tools and confidence to move forward faster.
Why Download This White Paper?
Inside, you'll discover how Xcite® combines a proprietary clonal suspension cell line, optimized plasmid architecture, and a refined production process to deliver exceptional performance across multiple AAV serotypes. The platform has been validated from shake flask to 250L bioreactors, with consistent results and a clear path to GMP.
You'll learn how teams using Xcite® have achieved:
- 2–9× higher titers compared to conventional systems
- Up to 94% full capsid ratios after polishing
- Gene-to-GMP timelines of approximately 12 months
But this isn't just about numbers. It's about building a manufacturing foundation that scales with your program, reduces risk, and supports regulatory readiness from day one.
Designed for Flexibility. Built for Speed.
Xcite® is more than a transfection platform. It's a strategic enabler for gene therapy developers. Its serotype-agnostic design means you can apply a unified process across different constructs, simplifying tech transfer and accelerating development. And with built-in analytical tools like 2D ddPCR and mass photometry, you gain deep insight into genome integrity and capsid quality.
The white paper also explores how Lonza's Design of Experiments (DoE) approach has helped optimize AAV production, boosting titers by up to 10-fold in some cases. These insights can help you fine-tune your own processes and avoid common pitfalls that delay progress.
Backed by a Global CDMO Leader
With decades of experience in viral vector manufacturing and a global network of GMP facilities, Lonza brings unmatched expertise to every stage of your program. The Xcite® platform is the result of this experience. It's designed to meet the real-world needs of gene therapy developers navigating a complex and competitive landscape.
Ready to Accelerate?
If you're looking to streamline your AAV development, reduce variability, and scale with confidence, this white paper is a must-read. It's packed with data, insights, and practical guidance to help you make informed decisions and move your program forward faster.
Fill out the form on this page to learn how Xcite® can help you go from gene to GMP with clarity and control.